AroCell AB: New application for AroCell TK 210 ELISA opens new opportunities for drug development research

Uppsala September 18, 2017                                                 PRESS RELEASE

New application for AroCell TK 210 ELISA opens new opportunities for drug development research

AroCell AB (publ) announces today that an abstract submitted by Kiran Kumar Jagarlamudi et al entitled "Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development" was accepted by the Purine and Pyrimidine Society for presentation at their annual meeting in Gdansk, Poland, September 20-24, 2017.

The purpose of this study was to evaluate the capacity of AroCell TK 210 ELISA to measure TK1 protein levels in cultured tumor cell lines. The effects of Doxorubicin on TK1 protein levels in extracts and media from CEM lymphoblastic cells as well as MDA-MB breast cancer cell cultures were studied for 24 hours. The results demonstrated that changes in intracellular and extracellular TK1 protein levels at different concentrations of DOX provide information about induction of TK1 in the cells, probably related to DNA damage, as well as release of TK1 protein into the media due to cytotoxicity.

"The results are very promising and demonstrate that AroCell TK 210 ELISA can be used to determine TK1 as a biomarker in in-vitro cell culture studies with drugs targeting cell proliferation and DNA repair. This means that our TK 210 ELISA test also has the potential to enable routine application in drug development studies" says Jan Stålemark AroCell CEO.

For additional information:



Jan Stålemark, CEO


AroCell AB (publ)


Tel: +46(0)706926206


info@arocell.com


www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 14.15 CET on 18 September 2017. 

About AroCell


AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.